Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2003

01-11-2003

Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes

Authors: Rosa Sánchez, Emilio Esteban, Isabel Palacio, Yolanda Fernández, Isabel Muñiz, Jose M. Vieitez, Joaquin Fra, Pilar Blay, Noemí Villanueva, Esther Uña, Beatriz Mareque, Enrique Estrada, Jose M. Buesa, Angel J. Lacave

Published in: Investigational New Drugs | Issue 4/2003

Login to get access
Metadata
Title
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes
Authors
Rosa Sánchez
Emilio Esteban
Isabel Palacio
Yolanda Fernández
Isabel Muñiz
Jose M. Vieitez
Joaquin Fra
Pilar Blay
Noemí Villanueva
Esther Uña
Beatriz Mareque
Enrique Estrada
Jose M. Buesa
Angel J. Lacave
Publication date
01-11-2003
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2003
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1026207519884

Other articles of this Issue 4/2003

Investigational New Drugs 4/2003 Go to the issue

OriginalPaper

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

OriginalPaper

Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells

OriginalPaper

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin

OriginalPaper

Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies

OriginalPaper

Effect of novel benzoylphenylurea derivatives on DNA polymerase α activity using the synthesome-based in vitro model system

OriginalPaper

A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits